Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
In a recent move, Mihael Hristos Polymeropoulos, President and CEO of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), has acquired additional shares of the company’s common stock. According to the SEC filing, Polymeropoulos purchased a total of 10,000 shares on March 5, 2025. The transactions were executed at prices ranging from $5.01 to $5.03 per share, bringing the total value of the acquisition to $50,200. The purchase comes as the company, currently valued at $299 million, maintains impressive gross profit margins of 94% and shows strong financial health with a current ratio of 4.39. InvestingPro analysis indicates the stock is currently undervalued.
Following these transactions, Polymeropoulos now holds 2,285,731 shares of Vanda Pharmaceuticals directly. His roles within the company include serving as Chairman of the Board, in addition to his executive leadership positions. The acquisitions reflect continued confidence in the company’s prospects by its top executive. According to InvestingPro, analysts expect net income growth this year, with 6 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Vanda Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -$0.08, compared to the forecasted -$0.17, and a revenue of $53.2 million, exceeding the forecast of $51.23 million. The company also announced the development of a novel antisense oligonucleotide therapeutic, VCA-894A, targeting Charcot-Marie-Tooth disease Type 2S, which has been granted orphan designation by the FDA. Analyst firm H.C. Wainwright raised its price target for Vanda Pharmaceuticals to $20.00, maintaining a Buy rating, following the company’s financial results. Additionally, Cantor Fitzgerald reiterated its Overweight rating and $13.00 price target, expressing optimism about Vanda’s commercial trajectory and pipeline productivity. Vanda also disclosed changes to its executive compensation, adjusting annual bonuses and base salaries, and awarding restricted stock units to top executives. These developments reflect Vanda Pharmaceuticals’ ongoing efforts in advancing its product pipeline and aligning executive compensation with company performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.